Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MB-CART2019.1 versus standard therapy in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma
NL-OMON54269Phase 2Not yet recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Jul 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zamtocabtagene autoleucel in diffuse large B-cell lymphoma (DLBCL) and mature B-cell lymphoma (3 arms), sponsored by Miltenyi Biomedicine GmbH. Primary endpoint: Event-free survival. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)mature B-cell lymphoma
Beyond the preview
Go deeper on NL-OMON54269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54269.